Publication | Open Access

Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study

Retrospective Cohort StudySurgical OncologyDefinitive SurgeryMedicineMelanomaImmune Checkpoint InhibitorDermatologyCancer TreatmentAdjuvant TherapyOncologyRadiation OncologyMolecular Oncology